Stimuli-responsive liposomes for the delivery of nucleic acid therapeutics

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 6, 2015, Pages 1575-1584

  Movahedi, Fatemeh ^a   Hu, Rebecca G ^b   Becker, David L ^b   Xu, Chenjie ^a  

^a Nanyang Technological University   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Controlled drug delivery; Nanomedicine; Nanoparticle; Nucleic acid therapeutics; Stimuli responsive liposome

Indexed keywords

BIOMOLECULES; DISEASES; GENE EXPRESSION; GENES; LIPOSOMES; MEDICAL NANOTECHNOLOGY; MOBILE SECURITY; NANOPARTICLES; NUCLEIC ACIDS;

BIOLOGICAL STABILITY; CLINICAL APPLICATION; ENVIRONMENTAL CHANGE; EXPERIMENTAL RESEARCH; INFLAMMATORY DISEASE; LATEST DEVELOPMENT; NUCLEIC ACID DELIVERIES; STIMULI-RESPONSIVE;

CONTROLLED DRUG DELIVERY;

LIPOFECTAMINE; LIPOPLEX; LIPOSOME; NUCLEIC ACID; DRUG CARRIER;

DISULFIDE BOND; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MAGNETIC FIELD; MICROENVIRONMENT; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PH; PULSATILE DRUG RELEASE; REVIEW; STATIC ELECTRICITY; ANIMAL;

ANIMALS; DRUG CARRIERS; HUMANS; LIPOSOMES; NUCLEIC ACIDS;

EID: 84937144547     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.03.006     Document Type: Review

References (96)

1. Videira M., Arranja A., Rafael D., Gaspar R. Preclinical development of siRNA therapeutics: towards the match between fundamental science and engineered systems. Nanomedicine 2014, 10:689-702.
2. Pushpendra S., Arvind P., Anil B. Nucleic acids as therapeutics. From Nucleic Acids Sequences to Molecular Medicine 2012, 19-45. Springer, Berlin Heidelberg. V.A. Erdmann, J. Barciszewski (Eds.).
3. Lehner R., Wang X., Marsch S., Hunziker P. Intelligent nanomaterials for medicine: carrier platforms and targeting strategies in the context of clinical application. Nanomedicine 2013, 9:742-757.
4. Mannell H., Pircher J., Fochler F., Stampnik Y., Rathel T., Gleich B., et al. Site directed vascular gene delivery in vivo by ultrasonic destruction of magnetic nanoparticle coated microbubbles. Nanomedicine 2012, 8:1309-1318.
5. Jones C.H., Chen C.-K., Ravikrishnan A., Rane S., Pfeifer B.A. Overcoming nonviral gene delivery barriers: perspective and future. Mol Pharm 2013, 10:4082-4098.
6. Nayerossadat N., Maedeh T., Ali P.A. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res 2012, 1:27.
7. Phillips M.A., Gran M.L., Peppas N.A. Targeted nanodelivery of drugs and diagnostics. Nano Today 2010, 5:143-159.
8. De Jong W.H., Borm P.J. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008, 3:133-149.
9. Gelperina S., Kisich K., Iseman M.D., Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005, 172:1487-1490.
10. Gao H., Yang Z., Zhang S., Cao S., Shen S., Pang Z., et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep 2013, 3.
11. Lee Y., Kataoka K. Delivery of Nucleic Acid Drugs. Advances in Polymer Science 2012, 249:95-134.
12. Kulkarni P.R., Yadav J.D., Vaidya K.A. Liposomes: a novel drug delivery system. Int J Curr Pharm Res 2011, 3:10-18.
13. Ziello J.E., Huang Y., Jovin I.S. Cellular endocytosis and gene delivery. Mol Med 2010, 16:222-229.
14. Yuan X., Naguib S., Wu Z. Recent advances of siRNA delivery by nanoparticles. Expert Opin Drug Deliv 2011, 8:521-536.
15. Lindner L.H., Hossann M. Factors affecting drug release from liposomes. Curr Opin Drug Discov Devel 2010, 13:111-123.
16. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965, 13:238-252.
17. Pinheiro M., Lucio M., Lima J.L., Reis S. Liposomes as drug delivery systems for the treatment of TB. Nanomedicine (Lond) 2011, 6:1413-1428.
18. Swami A., Shi J., Gadde S., Votruba A., Kolishetti N., Farokhzad O. Nanoparticles for targeted and temporally controlled drug delivery. Multifunctional Nanoparticles for Drug Delivery Applications 2012, 9-29. Springer US. S. Svenson, R.K. Prud'homme (Eds.).
19. Etheridge M.L., Campbell S.A., Erdman A.G., Haynes C.L., Wolf S.M., McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 2013, 9:1-14.
20. Jarver P., Coursindel T., Andaloussi S.E.L., Godfrey C., Wood M.J.A., Gait M.J. Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA. Mol Ther Nucleic Acids 2012, 1:e27.
21. Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siRNA therapeutics. Nat Mater 2013, 12:967-977.
22. Oh Y., Park T. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009, 61:850-862.
23. Portillo J., Kamar N., Melibary S., Quevedo E., Bergese S. Safety of liposome extended-release bupivacaine for postoperative pain control. Front Pharmacol 2014, 5:90.
24. Rafiyath S.M., Rasul M., Lee B., Wei G., Lamba G., Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol 2012, 1:10.
25. Alhajlan M., Alhariri M., Omri A. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. Antimicrob Agents Chemother 2013, 57:2694-2704.
26. Wang H., Zhao P., Su W., Wang S., Liao Z., Niu R., et al. PLGA/polymeric liposome for targeted drug and gene co-delivery. Biomaterials 2010, 31:8741-8748.
27. Shim G., Han S.E., Yu Y.H., Lee S., Lee H.Y., Kim K., et al. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J Control Release 2011, 155:60-66.
28. Costa P.M., Cardoso A.L., Mendonca L.S., Serani A., Custodia C., Conceicao M., et al. Tumor-targeted chlorotoxin-coupled nanoparticles for nucleic acid delivery to glioblastoma cells: a promising system for glioblastoma treatment. Mol Ther Nucleic Acids 2013, 2:e100.
29. San H., Yang Z.Y., Pompili V.J., Jaffe M.L., Plautz G.E., Xu L., et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther 1993, 4:781-788.
30. Porteous D.J., Dorin J.R., McLachlan G., Davidson-Smith H., Davidson H., Stevenson B.J., et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997, 4:210-218.
31. Pakunlu R.I., Wang Y., Saad M., Khandare J.J., Starovoytov V., Minko T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 2006, 114:153-162.
32. Lappalainen K., Urtti A., Jääskeläinen I., Syrjänen K., Syrjänen S. Cationic liposomes mediated delivery of antisense oligonucleotides targeted to HPV 16 E7 mRNA in CaSki cells. Antivir Res 1994, 23:119-130.
33. Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005, 65:6910-6918.
34. Markov O.O., Mironova N.L., Maslov M.A., Petukhov I.A., Morozova N.G., Vlassov V.V., et al. Novel cationic liposomes provide highly efficient delivery of DNA and RNA into dendritic cell progenitors and their immature offsets. J Control Release 2012, 160:200-210.
35. McCaskill J., Singhania R., Burgess M., Allavena R., Wu S., Blumenthal A., et al. Efficient biodistribution and gene silencing in the lung epithelium via intravenous liposomal delivery of siRNA. Mol Ther Nucleic Acids 2013, 2:e96.
36. Saul J.M., Annapragada A., Natarajan J.V., Bellamkonda R.V. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 2003, 92:49-67.
37. Lestini B.J., Sagnella S.M., Xu Z., Shive M.S., Richter N.J., Jayaseharan J., et al. Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J Control Release 2002, 78:235-247.
38. Mura S., Nicolas J., Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater 2013, 12:991-1003.
39. Yatvin M.B., Weinstein J.N., Dennis W.H., Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978, 202:1290-1293.
40. Zhu L., Torchilin V.P. Stimulus-responsive nanopreparations for tumor targeting. Integr Biol (Camb) 2013, 5:96-107.
41. Lu Y., Sun W., Gu Z. Stimuli-responsive nanomaterials for therapeutic protein delivery. J Control Release 2014, 194:1-19.
42. Kikuchi A., Okano T. Pulsatile drug release control using hydrogels. Adv Drug Deliv Rev 2002, 54:53-77.
43. Nakayama M., Okano T., Miyazaki T., Kohori F., Sakai K., Yokoyama M. Molecular design of biodegradable polymeric micelles for temperature-responsive drug release. J Control Release 2006, 115:46-56.
44. Yang H.W., Hua M.-Y., Liu H.L., Huang C.Y., Tsai R.Y., Lu Y.J., et al. Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas. Biomaterials 2011, 32:6523-6532.
45. Mykhaylyk O., Sánchez-Antequera Y., Vlaskou D., Hammerschmid E., Anton M., Zelphati O., et al. Liposomal magnetofection. Liposomes 2010, 487-525. Humana Press. V. Weissig (Ed.).
46. Scherer F., Anton M., Schillinger U., Henke J., Bergemann C., Kruger A., et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002, 9:102-109.
47. Xenariou S., Griesenbach U., Ferrari S., Dean P., Scheule R.K., Cheng S.H., et al. Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo. Gene Ther 2006, 13:1545-1552.
48. Hirao K., Sugita T., Kubo T., Igarashi K., Tanimoto K., Murakami T., et al. Targeted gene delivery to human osteosarcoma cells with magnetic cationic liposomes under a magnetic field. Int J Oncol 2003, 22:1065-1071.
49. Wang C., Ding C., Kong M., Dong A., Qian J., Jiang D., et al. Tumor-targeting magnetic lipoplex delivery of short hairpin RNA suppresses IGF-1R overexpression of lung adenocarcinoma A549 cells in vitro and in vivo. Biochem Biophys Res Commun 2011, 410:537-542.
50. Namiki Y., Namiki T., Yoshida H., Ishii Y., Tsubota A., Koido S., et al. A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery. Nat Nanotechnol 2009, 4:598-606.
51. Vainauska D., Kozireva S., Karpovs A., Čistjakovs M., Bariševs M. A novel approach for nucleic acid delivery into cancer cells. Medicina (Kaunas) 2012, 48:324-329.
52. Baryshev M., Vainauska D., Kozireva S., Karpovs A. New device for enhancement of liposomal magnetofection efficiency of cancer cells. World Acad Sci Eng Technol 2011, 2011:306-309.
53. Lee Y.J., Hou Z.-Z., Curetty L., Cho J.M., Corry P.M. Mechanism of synergistic effects of cytokine and hyperthermia on cytotoxicity in HT-29 and MCF-7 cells: expression of MnSOD gene. J Therm Biol 1993, 18:269-274.
54. Fleischmann W.R., Fleischmann C.M. Enhancement of MuIFN-gamma antitumor effects by hyperthermia: sequence dependence and time dependence of hyperthermia. J Biol Regul Homeost Agents 1994, 8:101-107.
55. Bouhon I.A., Shinkai M., Honda H., Mizuno M., Wakabayashi T., Yoshida J., et al. Synergism between mild hyperthermia and interferon-β gene expression. Cancer Lett 1999, 139:153-158.
56. Issels R.D. Hyperthermia adds to chemotherapy. Eur J Cancer 2008, 44:2546-2554.
57. Mohamed F., Marchettini P., Stuart O.A., Urano M., Sugarbaker P. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003, 10:463-468.
58. Rapoport N. Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for drug delivery to cancer. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012, 4:492-510.
59. Alkan-Onyuksel H., Demos S.M., Lanza G.M., Vonesh M.J., Klegerman M.E., Kane B.J., et al. Development of inherently echogenic liposomes as an ultrasonic contrast agent. J Pharm Sci 1996, 85:486-490.
60. Huang S.L., Hamilton A.J., Nagaraj A., Tiukinhoy S.D., Klegerman M.E., McPherson D.D., et al. Improving ultrasound reflectivity and stability of echogenic liposomal dispersions for use as targeted ultrasound contrast agents. J Pharm Sci 2001, 90:1917-1926.
61. Huang S.L., Hamilton A.J., Pozharski E., Nagaraj A., Klegerman M.E., McPherson D.D., et al. Physical correlates of the ultrasonic reflectivity of lipid dispersions suitable as diagnostic contrast agents. Ultrasound Med Biol 2002, 28:339-348.
62. Buchanan K.D., Huang S., Kim H., Macdonald R.C., McPherson D.D. Echogenic liposome compositions for increased retention of ultrasound reflectivity at physiologic temperature. J Pharm Sci 2008, 97:2242-2249.
63. Negishi Y., Fukuyama T., Endo Y., Suzuki R., Tanaka K., Sawamura K., et al. 553. Development of echo-contrast gas entrapping liposome as gene and siRNA delivery tool. Mol Ther 2006, 13:S213.
64. Ferrara K.W. Driving delivery vehicles with ultrasound. Adv Drug Deliv Rev 2008, 60:1097-1102.
65. Rychak J.J., Klibanov A.L. Nucleic acid delivery with microbubbles and ultrasound. Adv Drug Deliv Rev 2014, 72:82-93.
66. Zacharakis E., Ahmed H.U., Ishaq A., Scott R., Illing R., Freeman A., et al. The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. Int Br J Urol 2008, 102:782-792.
67. Schroeder A., Avnir Y., Weisman S., et al. Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. Langmuir 2007, 23:4019-4025.
68. Schroeder A., Avnir Y., Weisman S., Najajreh Y., Gabizon A., Talmon Y., et al. Rapid skin permeabilization by the simultaneous application of dual-frequency, high-intensity ultrasound. J Control Release 2012, 163:154-160.
69. Un K., Kawakami S., Suzuki R., Maruyama K., Yamashita F., Hashida M. Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine therapy. Biomaterials 2010, 31:7813-7826.
70. Koebis M., Kiyatake T., Yamaura H., Nagano K., Higashihara M., Sonoo M., et al. Ultrasound-enhanced delivery of Morpholino with Bubble liposomes ameliorates the myotonia of myotonic dystrophy model mice. Sci Rep 2013, 3:2242.
71. Endo-Takahashi Y., Negishi Y., Nakamura A., Ukai S., Ooaku K., Oda Y., et al. Systemic delivery of miR-126 by miRNA-loaded Bubble liposomes for the treatment of hindlimb ischemia. Sci Rep 2014, 4.
72. Yin T., Wang P., Li J., Wang Y., Zheng B., Zheng R., et al. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes. Biomaterials 2014, 35:5932-5943.
73. Zhao Y.Z., Du L.N., Lu C.T., Jin Y.G., Ge S.P. Potential and problems in ultrasound-responsive drug delivery systems. Int J Nanomedicine 2013, 8:1621-1633.
74. El-Sayed M.E., Hoffman A.S., Stayton P.S. Smart polymeric carriers for enhanced intracellular delivery of therapeutic macromolecules. Expert Opin Biol Ther 2005, 5:23-32.
75. Ganta S., Devalapally H., Shahiwala A., Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 2008, 126:187-204.
76. Saito G., Swanson J.A., Lee K.D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 2003, 55:199-215.
77. Deshpande P.P., Biswas S., Torchilin V.P. Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond) 2013, 8:1509-1528.
78. Ajmani P.S., Tang F., Krishnaswami S., Meyer E.M., Sumners C., Hughes J.A. Enhanced transgene expression in rat brain cell cultures with a disulfide-containing cationic lipid. Neurosci Lett 1999, 277:141-144.
79. Balakirev M., Schoehn G., Chroboczek J. Lipoic acid-derived amphiphiles for redox-controlled DNA delivery. Chem Biol 2000, 7:813-819.
80. Wang M., Alberti K., Varone A., Pouli D., Georgakoudi I., Xu Q. Enhanced intracellular siRNA delivery using bioreducible lipid-like nanoparticles. Adv Healthc Mater 2014, 3:1398-1403.
81. Gabriele C., Daniele P., Laura C., Roberto C., Sandra R. Bioreducible liposomes for gene delivery: from the formulation to the mechanism of action. PLoS One 2010, 5.
82. Bersani S., Vila-Caballer M., Brazzale C., Barattin M., Salmaso S. pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine) decorated liposomes for the delivery of gemcitabine to cancer cells. European Journal of Pharmaceutics and Biopharmaceutics 2014, 88:670-682.
83. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nature 2005, 4:145-160.
84. Liu X., Huang G. Formation strategies, mechanism of intracellular delivery and potential clinical applications of pH-sensitive liposomes. Asian J Pharm Sci 2013, 8:319-328.
85. Ropert C., Lavignon M., Dubernet C., Couvreur P., Malvy C. Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. Biochem Biophys Res Commun 1992, 183:879-885.
86. Ponnappa B.C., Dey I., Tu G.C., Zhou F., Aini M., Cao Q.N., et al. In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats. J Pharmacol Exp Ther 2001, 297:1129-1136.
87. Sato Y., Hatakeyama H., Sakurai Y., Hyodo M., Akita H., Harashima H. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J Control Release 2012, 163:267-276.
88. Sakurai Y., Hatakeyama H., Sato Y., Hyodo M., Akita H., Ohga N., et al. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system. J Control Release 2014, 173:110-118.
89. Zhao P., Chenxiao W., Erhu F., Xiaoming L., Guobin W., Qiang T. Co-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapy. PLoS One 2014, 9:e92924.
90. Ta T and Porter TM. Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. Journal of Controlled Release. 169: 112-125.
91. Bouhon I., Shinkai M., Honda H., Kobayashi T. Enhancement of cytokine expression in transiently transfected cells by magnetoliposome mediated hyperthermia. Cytotechnology 1997, 25:231-234.
92. Dave N., Liu J. Protection and promotion of UV radiation-induced liposome leakage via DNA-directed assembly with gold nanoparticles. Adv Mater 2011, 23:3182-3186.
93. Wan Y., Han J., Fan G., Zhang Z., Gong T., Sun X. Enzyme-responsive liposomes modified adenoviral vectors for enhanced tumor cell transduction and reduced immunogenicity. Biomaterials 2013, 34:3020-3030.
94. El-Hamed F., Dave N., Liu J. Stimuli-responsive releasing of gold nanoparticles and liposomes from aptamer-functionalized hydrogels. Nanotechnology 2011, 22:494011.
95. Mo R., Jiang T., Gu Z. Enhanced anticancer efficacy by ATP-mediated liposomal drug delivery. Angew Chem 2014, 126:5925-5930.
96. MacEwan S.R., Callahan D.J., Chilkoti A. Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery. Nanomedicine (Lond) 2010, 5:793-806.